First trimester maternal serum screening using biochemical markers PAPP-A and Free β-hCG for down syndrome, patau syndrome and edward syndrome

被引：52

作者：

Shiefa S. ^{[1
]}

Amargandhi M. ^{[1
]}

Bhupendra J. ^{[1
]}

Moulali S. ^{[1
]}

Kristine T. ^{[1
]}

机构：

[1] SRL Diagnostics, Fortis Healthcare Enterprise, Clinical Biochemist, 64, Dubai Health Care City

来源：

Indian Journal of Clinical Biochemistry | 2013年 / 28卷 / 1期

关键词：

Down syndrome; Edward syndrome; Free; β-hCG; Nuchal translucency; PAPP-A; Patau syndrome;

D O I：

10.1007/s12291-012-0269-9

中图分类号：

学科分类号：

摘要：

The first trimester screening programme offers a noninvasive option for the early detection of aneuploidy pregnancies. This screening is done by a combination of two biochemical markers i.e. serum free β-human chorionic gonadotrophin (free β-hCG) and pregnancy associated plasma protein A (PAPP-A), maternal age and fetal nuchal translucency (NT) thickness at 11 + 0-13 + 6 weeks of gestation. A beneficial consequence of screening is the early diagnosis or trisomies 21, 18 and 13. At 11 + 0-13 + 6 weeks, the relative prevalence of trisomies 18 and 13 to trisomy 21 are found to be one to three and one to seven, respectively. All three trisomies are associated with increased maternal age, increased fetal NT and decreased PAPP-A, but in trisomy 21 serum free β-hCG is increased whereas in trisomies 18 and 13 free β-hCG is decreased. © 2012 Association of Clinical Biochemists of India.

引用

页码：3 / 12

页数：9

共 49 条

[1]

Snijders R.J.M., Sundberg K., Holzgreve W., Henry G., Nicolaides K.H., Maternal age- and gestation-specific risk for trisomy 21, Ultrasound Obstet Gynecol, 13, pp. 167-170, (1999)

[2]

Wilson R.D., Amended Canadian Guideline for prenatal diagnosis (2005) change to 2005 - Techniques for prenatal diagnosis. SOGC Clinical Practice Guidelines, No. 168, November 2005, J Obstet Gynaecol Can, 27, pp. 1048-1054, (2005)

[3]

Bindra R., Liao V.H.A., Spencer K., Nicolaides K.H., One stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: A prospective study of 15030 pregnancies, Ultrasound Obstet Gynecol, 20, pp. 219-225, (2002)

[4]

Nicolaides K.H., Screening for fetal aneuploides at 11 to 13 weeks, Prenat Diagn, 1, 31, pp. 7-15, (2011)

[5]

Dugoff L., Hobbins J.C., Malone F.D., Et al., Quad screen as a predictor of adverse pregnancy outcome, Obstet Gynecol, 106, pp. 260-267, (2005)

[6]

Nicholas J.W., Wayne J.H., Allan K.H., Antenatal screening for Down's syndrome with the quadruple test, Lancet, 361, 9360, pp. 835-836, (2003)

[7]

Wald N.J., Kennard A., Hackshaw A., McGuire A., Antenatal screening for Down's syndrome published erratum appears in, J Med Screen, 5, (1998)

[8]

Petrovic I., Marina D., Juan C.K., The role of pregnancy associated plasma protein -A (PAPP-A) in the identification of coronary artery disease activity, Acta Fac Med Naissensis, 24, 4, pp. 183-188, (2007)

[9]

Fialova L., Malbohan I.M., Pregnancy-associated plasma protein-A (PAPP-A): Theoretical and clinical aspects, Bratisl Lek Listy, 103, pp. 194-205, (2002)

[10]

Overgaard M.T., Oxvig C., Christiansen M., Lawrence J.B., Conover C.A., Gleich G.J., Messenger ribonucleic acid levels of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein: Expression in human reproductive and non reproductive tissues, Biol Reprod, 61, pp. 1083-1089, (1999)

← 1 2 3 4 5 →